DSI Releases 2 New Non-Interpretive Reading Room Use Cases
use cases, artificial intelligence, reading room
Read moreMain Content
Presents to FDA on Oversight Considerations for GenAI Medical Devices
Nov. 21, 2024
The ® (®) presented Nov. 20-21 at the U.S. Food and Drug Administration (FDA) Digital Health Advisory Committee (DHAC) “Total Product Lifecycle Considerations for Generative AI-Enabled Devices.” Bernardo Bizzo, MD, PhD, Data Science Institute® Associate Chief Science Officer, represented the College at the meeting.
The meeting focused on novel oversight challenges and opportunities specific to FDA-regulated generative artificial intelligence (AI)-enabled devices. Per FDA’s , generative AI emulates the structure and characteristics of input data in order to generate derived synthetic content, such as images, videos, audio, text and other digital content; this typically is done by approximating the statistical distribution of the input data.
Dr. Bizzo provided overviews of the Recognized Center for Healthcare-AI (ARCH-AI) quality assurance program, including the recently announced Assess-AI registry that provides radiology facilities with analytics on clinical AI performance over time as compared to national benchmarks. He discussed how DSI programs and similar initiatives could be leveraged to help ensure the safety, effectiveness, and quality uses of generative AI-enabled devices.
For more information about ’s AI-related initiatives, visit the DSI website. For questions about AI oversight and digital health policy, contact Michael Peters, Senior Director, Government Affairs.
The meeting focused on novel oversight challenges and opportunities specific to FDA-regulated generative artificial intelligence (AI)-enabled devices. Per FDA’s , generative AI emulates the structure and characteristics of input data in order to generate derived synthetic content, such as images, videos, audio, text and other digital content; this typically is done by approximating the statistical distribution of the input data.
Dr. Bizzo provided overviews of the Recognized Center for Healthcare-AI (ARCH-AI) quality assurance program, including the recently announced Assess-AI registry that provides radiology facilities with analytics on clinical AI performance over time as compared to national benchmarks. He discussed how DSI programs and similar initiatives could be leveraged to help ensure the safety, effectiveness, and quality uses of generative AI-enabled devices.
For more information about ’s AI-related initiatives, visit the DSI website. For questions about AI oversight and digital health policy, contact Michael Peters, Senior Director, Government Affairs.
Related News
Direct Supervision for Contrast Studies
We recommend that sites follow the CT and MR Accreditation requirements for onsite supervision of contrast administration and management.
Read moreProvides Detailed Summary of 2025 HOPPS Final Rule
The ® outlined issues that impact radiology, including updates to imaging ambulatory payment classifications and requirements for the Hospital Outpatient Quality Reporting program. The rule changes take effect Jan. 1.
Read more